A phase II clinical trial evaluating ACT-777991 for Vitiligo
Latest Information Update: 27 Nov 2025
At a glance
- Drugs ACT-777991 (Primary)
- Indications Vitiligo
- Focus Proof of concept; Therapeutic Use
Most Recent Events
- 30 Oct 2025 According to Idorsia media release, the trial is expected to begin in 2026.
- 04 Nov 2024 New trial record